Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, causes considerable weight loss, but data are lacking with respect to its effects on cardiovascular outcomes. METHODS In this international, double-blind, randomized, placebo-controlled trial, we randomly assigned, in a 1:1 ratio, 731 patients with heart failure, an ejection fraction of at least 50%, and a body-mass index (the weight in kilograms divided by the square of the height in meters) of at least 30 to receive tirzepatide (up to 15 mg subcutaneously once per week) or placebo for at least 52 weeks. The two primary end points were a composite of adjudicated death from cardiovascular causes or a worsening heart-failure event (assessed in a time-to-first-event analysis) and the change from baseline to 52 weeks in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating better quality of life). RESULTS A total of 364 patients were assigned to the tirzepatide group and 367 to the placebo group; the median duration of follow-up was 104 weeks. Adjudicated death from cardiovascular causes or a worsening heart-failure event occurred in 36 patients (9.9%) in the tirzepatide group and in 56 patients (15.3%) in the placebo group (hazard ratio, 0.62; 95% confidence interval [CI], 0.41 to 0.95; P…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the SUMMIT trial (for tirzepatide) showed a reduction in events regarding time to cardiovascular death or worsening heart failure over 104 weeks (HR 0•62, 0•41-0•95), 79”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [79]
In the citing paper
“Apart from improvements in multiple cardiometabolic risk factors, tirzepatide also improves various obesity-related complications such as obstructive sleep apnoea (OSA), metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction [28–30].”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [30]
In the citing paper
“Both semaglutide and tirzepatide reduce the severity of heart failure with preserved ejection fraction (65, 66).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [66]
In the citing paper
“Tirzepatide also lowers CRP levels in clinical trials in people with heart failure with preserved ejection fraction, or OSA (19, 66).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [66]
In the citing paper
“In the SUMMIT trial (Study of Tirzepatide in Participants With Heart Failure With Preserved Ejection Fraction and Obesity), tirzepatide reduced the risk of the composite of cardiovascular death and worsening HF events.23”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [23]
27 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669
Self-citationSemaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
Kosiborod, M. N., Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Treppendahl, M. B., Verma, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2313917 · Cited by 758
Self-citationPacker, M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.509 · Cited by 656
Self-citationTirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541
The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEF
Savji, N., Meijers, W. C., Bartz, T. M., Bhambhani, V., Cushman, M., Nayor, M., Kizer, J. R., Sarma, A., Blaha, M. J., Gansevoort, R. T., et al. (2018) · JACC: Heart Failure · doi:10.1016/j.jchf.2018.05.018 · Cited by 499
Borlaug, B. A., Jensen, M. D., Kitzman, D. W., Lam, C. S. P., Obokata, M., & Rider, O. J. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvac120 · Cited by 450
Self-citationPaulus, W. J., & Zile, M. R. (2021) · Circulation Research · doi:10.1161/circresaha.121.318159 · Cited by 393
Self-citationKosiborod, M. N., Deanfield, J., Pratley, R., Borlaug, B. A., Butler, J., Davies, M. J., Emerson, S. S., Kahn, S. E., Kitzman, D. W., Lingvay, I., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01643-x · Cited by 308
Self-citation
Cited by
Palaniappan, L. P., Allen, N. B., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Bansal, N., Currie, M. E., Earlie, R. S., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001412 · Cited by 242
GLP-1-based therapies for diabetes, obesity and beyond
Drucker, D. J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01183-8 · Cited by 236
“…for GLP-1 medicines include the SELECT cardiovascular outcomes trial with semaglutide 108 , the tirzepatide obstructive sleep apnoea trials 122 , semaglutide and, separately, tirzepatide for heart failure outcomes 113,157 , and semaglutide for osteoarthritis and metabolic liver disease 121,126 .”
9. pharmacologic approaches to glycemic treatment: standards of care in diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s009 · Cited by 263
Blüher, M. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16263 · Cited by 175
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E., Sato, K., Teramoto, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Circulation Journal · doi:10.1253/circj.cj-25-0002 · Cited by 191
Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement
Mensah, G. A., Arnold, N., Prabhu, S. D., Ridker, P. M., & Welty, F. K. (2025) · JACC · doi:10.1016/j.jacc.2025.08.047 · Cited by 177
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s010 · Cited by 225
Diagnosis and Treatment of Type 2 Diabetes in Adults: A Review
Kalyani, R. R., Neumiller, J. J., Maruthur, N. M., & Wexler, D. J. (2025) · JAMA · doi:10.1001/jama.2025.5956 · Cited by 204
Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure
Kramer, C. M., Borlaug, B. A., Zile, M. R., Ruff, D., DiMaria, J. M., Menon, V., Ou, Y., Zarante, A. M., Hurt, K. C., Murakami, M., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.11.001 · Cited by 200
Self-citationThe Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction
Packer, M. (2025) · JACC · doi:10.1016/j.jacc.2025.06.055 · Cited by 173
Self-citationBorlaug, B. A., Zile, M. R., Kramer, C. M., Baum, S. J., Hurt, K., Litwin, S. E., Murakami, M., Ou, Y., Upadhyay, N., & Packer, M. (2025) · Nature Medicine · doi:10.1038/s41591-024-03374-z · Cited by 166
“The SUMMIT primary results, trial protocol and statistical analysis plan have been published, and the protocol and statistical analysis plan are included in Supplementary Information 16 .”
InfluentialSelf-citationMozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.04.023 · Cited by 154
“…of GLP-1s include improved cardiometabolic risks, fewer major adverse cardiovascular events [23], decreased mortality in heart failure [24 – 28], and improvements in obstructive sleep apnea [12,29], prediabetes [30,31], chronic kidney disease [32], knee osteoarthritis [33], substance use…”
Theodorakis, N., & Nikolaou, M. (2025) · Biomolecules · doi:10.3390/biom15020213 · Cited by 175
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity · doi:10.1002/oby.24336 · Cited by 143
“…of GLP-1s include improved cardiome-tabolic risks, fewer major adverse cardiovascular events [22], decreased mortality in heart failure [23 – 27], and improvements in obstructive sleep apnea [21, 28], prediabetes [29, 30], chronic kidney disease [31], knee osteoarthritis [32], substance use…”
Nadolsky, K., Garvey, W. T., Agarwal, M., Bonnecaze, A., Burguera, B., Chaplin, M. D., Griebeler, M. L., Harris, S. R., Schellinger, J. N., Simonetti, J., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.07.017 · Cited by 141
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Peikert, A., Vaduganathan, M., Claggett, B. L., Kulac, I. J., Litwin, S. E., Zile, M. R., Desai, A. S., Jhund, P. S., Butt, J. H., Lam, C. S. P., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf057 · Cited by 132
“53 15 To date, the primary basis of defining the obesity-related HFpEF sub-phenotype has been the concomitant finding of a BMI ≥ 30 kg/ m 2 , fulfilling the WHO definition of obesity.”
Self-citationRosen, C. J., & Ingelfinger, J. R. (2026) · New England Journal of Medicine · doi:10.1056/nejmra2500106 · Cited by 135
Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists
Galli, M., Benenati, S., Laudani, C., Simeone, B., Sarto, G., Ortega‐Paz, L., Rocco, E., Bernardi, M., Spadafora, L., D’Amario, D., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.027 · Cited by 140
Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits
Wong, C. K., & Drucker, D. J. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194751 · Cited by 112
Once-monthly maridebart cafraglutide for the treatment of obesity—a phase 2 trial
Jastreboff, A. M., Ryan, D. H., Bays, H. E., Ebeling, P. R., Mackowski, M. G., Philipose, N., Ross, L., Liu, Y., Burns, C. E., Abbasi, S. A., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2504214 · Cited by 110
Sattar, N., Neeland, I. J., Dahlqvist Leinhard, O., Fernández Landó, L., Bray, R., Linge, J., & Rodriguez, A. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00027-0 · Cited by 131
McGowan, B., Ciudin, A., Baker, J. L., Busetto, L., Dicker, D., Frühbeck, G., Goossens, G. H., Monami, M., Sbraccia, P., Martinez-Tellez, B., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03978-z · Cited by 100
“Three trials (two with semaglutide 45,46 and one with tirzepa-tide 44 ) included patients with previously diagnosed heart failure; thus, individual study results are presented.”
2026 ESC Guidelines for the management of heart failure
Køber, L., Adamo, M., Ruwald, A., Tomasoni, D., Anderson, L., Andersson, C., Brugts, J. J., Chioncel, O. D., Donal, E., Ferdinandy, P., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag100 · Cited by 159
Ndumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 160
Romeo, S., Vidal‐Puig, A., Husain, M., Ahima, R. S., Arca, M., Bhatt, D. L., Diehl, A. M., Fontana, L., Foo, R., Frühbeck, G., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf314 · Cited by 109
“246 Given that loss of visceral adipose tissue is accompanied by loss of liver fat, the logical next step was to evaluate GLP-1 receptor agonists as a treatment for MASLD/MASH.”
Heart Failure with Preserved Ejection Fraction
Cannata, A. N., & McDonagh, T. A. (2025) · New England Journal of Medicine · doi:10.1056/nejmcp2305181 · Cited by 109
Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Dahl, K., Toubro, S., Dey, S., Duque do Vale, R., Flint, A., Gasiorek, A., Heydorn, A., Jastreboff, A. M., Key, C., Petersen, S. B., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01185-7 · Cited by 80
2025 ACC Scientific Statement on the Management of Obesity in Adults With Heart Failure
Kittleson, M. M., Benjamin, E. J., Blumer, V., Harrington, J., Januzzi, J. L., McMurray, J. J. V., & Vest, A. R. (2025) · JACC · doi:10.1016/j.jacc.2025.05.008 · Cited by 79
Mutruc, V., Bologa, C., Șorodoc, V., Ceasovschih, A., Morărașu, B. C., Șorodoc, L., Catar, O., & Lionte, C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082833 · Cited by 89
Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update
Pedersen, S. D., Manjoo, P., Dash, S., Jain, A., Pearce, N., & Poddar, M. (2025) · Canadian Medical Association Journal · doi:10.1503/cmaj.250502 · Cited by 78
Reddy, Y. N. V., Tada, A., Obokata, M., Carter, R. E., Kaye, D. M., Handoko, M. L., Andersen, M. J., Sharma, K., Tedford, R. J., Redfield, M. M., et al. (2025) · Circulation · doi:10.1161/circulationaha.124.072156 · Cited by 82
“34 Patients with HFpEF and obesity also derive greater symptomatic benefit from sodium-glucose cotransporter-2 inhibitors.”
Self-citationDecoding the Liver-Heart Axis in Cardiometabolic Diseases
Capone, F., Vacca, A., Bidault, G., Sarver, D. C., Kamińska, D., Strocchi, S., Vidal‐Puig, A., Greco, C. M., Lusis, A. J., & Schiattarella, G. G. (2025) · Circulation Research · doi:10.1161/circresaha.125.325492 · Cited by 81
Zile, M. R., Borlaug, B. A., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ou, Y., Weerakkody, G. J., Hurt, K. C., Kanu, C., et al. (2025) · Circulation · doi:10.1161/circulationaha.124.072679 · Cited by 74
“23 It should be noted that marked weight loss in patients with obesity produced by bariatric surgery or intense calorie restriction leads to 2-to 5-fold increases in NT-proBNP, 37,38 potentially related to greater ventricular distention as a result of relief of adiposity-related chamber constraint.”
Self-citationObesity accelerates cardiovascular ageing
Ruperez, C., Madeo, F., de Cabo, R., Kroemer, G., & Abdellatif, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf216 · Cited by 73
“261”
WAQAS, S. A., Sohail, M. U., Saad, M., Minhas, A. M. K., Greene, S. J., Fudim, M., Fonarow, G. C., Abramov, D., Khan, M. S., & Ahmed, R. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.01.022 · Cited by 73
The expanding landscape of GLP-1 medicines
Drucker, D. J. (2026) · Nature Medicine · doi:10.1038/s41591-025-04124-5 · Cited by 83
“The cardiovascular benefits of semaglutide and tirzepatide extend to patients with HFpEF, with evidence for symptomatic improvement, reduced rates of cardiovascular death and decreased need for hospital visits and intensification of therapy 23,24 .”
Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction
Krüger, N., Schneeweiss, S., Fuse, K., Matseyko, S., Sreedhara, S. K., Hahn, G., Schunkert, H., & Wang, S. V. (2025) · JAMA · doi:10.1001/jama.2025.14092 · Cited by 66
Gilbert, O., Gulati, M., Gluckman, T. J., Kittleson, M. M., Rikhi, R., Saseen, J. J., & Tchang, B. G. (2025) · JACC · doi:10.1016/j.jacc.2025.05.024 · Cited by 65
Peikert, A., Fontana, M., Solomon, S. D., & Thum, T. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf524 · Cited by 74
“130,131 While evidence from clinical trials remains limited, experimental data indicate that combined GLP-1/GIP agonists may further limit diabetes-related cardiac fibrosis.”
Tirzepatide for overweight and obesity management
Hamza, M., Papamargaritis, D., & Davies, M. J. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2436595 · Cited by 43
“Participants were randomized to receive either tirzepatide MTD ( n = 364), or placebo ( n = 367) [67].”
InfluentialStolfo, D., Iacoviello, M., Chioncel, O. D., Anker, M. S., Bayés‐Genís, A., Braunschweig, F., Cannata, A. N., Hadidi, S. E., Filippatos, G., Jhund, P. S., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3642 · Cited by 62
“26–28 Chronic kidney disease is a frequent real or perceived barrier to the optimization of HF GDMT, but GDMT has evidence of benefit and safety also in patients with chronic kidney disease up to stage 3b/4, 29 and therefore during the processes of therapeutic revision and reassessment of…”
Mechano-energetic uncoupling in heart failure
Aksentijević, D., Sedej, S., Fauconnier, J., Paillard, M., Abdellatif, M., Streckfuß‐Bömeke, K., Ventura‐Clapier, R., van der Velden, J., de Boer, R. A., Bertero, E., et al. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01167-6 · Cited by 60
Finerenone, Obesity, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction
Butt, J. H., Henderson, A. D., Jhund, P. S., Claggett, B. L., Desai, A. S., Lay‐Flurrie, J., Viswanathan, P., Lage, A. Z., Scheerer, M. F., Lam, C. S. P., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.10.111 · Cited by 56
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E. T., Sato, K., TERAMOTO, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.02.014 · Cited by 67
Metabolic rewiring and inter-organ crosstalk in diabetic HFpEF
Luo, L., Zuo, Y., & Dai, L. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02707-7 · Cited by 56
“The SUMMIT trial demonstrated that tirzepatide therapy reduced the composite risk of cardiovascular mortality or heart failure progression compared to placebo and enhanced health-related outcomes in obese individuals with HFpEF [141].”
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease
Schwabe, R. F., Tacke, F., Sugimoto, A., & Friedman, S. L. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101421 · Cited by 70
“229,208,373,241,242,374 Furthermore, single, dual and triple GLP-1/GIP/glucagon receptor agonists appear to have a good safety pro fi le, eliciting few adverse effects, which are mostly gastrointestinal.”
Savarese, G., Schiattarella, G. G., Lindberg, F., Anker, M. S., Bayés‐Genís, A., Bäck, M., Braunschweig, F., Bucciarelli‐Ducci, C., Butler, J., Cannata, A. N., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3676 · Cited by 58
Lam, C. S. P., Rodríguez, Á., Aminian, A., Ferrannini, E., Heerspink, H. J. L., Jastreboff, A. M., Laffin, L. J., Pandey, A., Ray, K. K., Ridker, P. M., et al. (2025) · Obesity · doi:10.1002/oby.24332 · Cited by 59
“…trial showed that among patients with heart failure with preserved ejection fraction and obesity; treatment with tirzepatide (up to 15 mg once per week) led to a lower risk of a composite of death from cardiovascular causes or worsening heart failure and improved health status versus placebo [43].”
Self-citationPacker, M., Zile, M. R., Kramer, C. M., Murakami, M., Ou, Y., & Borlaug, B. A. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.009 · Cited by 49
Self-citationKarakasis, P., Vlachos, K. G., Antoniadis, A. P., Siontis, K. C., Patoulias, D., Fragakis, N., & Mantzoros, C. S. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156463 · Cited by 56
Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)
Patel, S., & Niazi, S. K. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17081036 · Cited by 54
“In 731 patients with HFpEF and obesity, tirzepatide demonstrated a 38% reduction in the composite endpoint of cardiovascular death or worsening heart failure events (HR 0.62, 95% CI 0.41–0.95), representing one of the most significant treatment effects ever observed in HFpEF [90].”
InfluentialGunnarsson, S., Vito, O., & Unwin, R. J. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00499.2025 · Cited by 52
Theodorakis, N., & Nikolaou, M. (2025) · Biomedicines · doi:10.3390/biomedicines13010135 · Cited by 50
“SUMMIT thus suggested that tirzepatide’s profound metabolic and weight benefits translate into measurable improvements in HFpEF outcomes irrespective of diabetes status [51].”
Borlaug, B. A., Zile, M. R., Kramer, C. M., Ye, W., Ou, Y., Hurt, K. C., Murakami, M., & Packer, M. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.04.059 · Cited by 51
Self-citationLee, D. S. M., Cardone, K. M., Zhang, D. Y., Tsao, N. L., Abramowitz, S. A., Sharma, P., DePaolo, J. S., Conery, M., Aragam, K. G., Biddinger, K. J., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02140-2 · Cited by 51
“Mendelian randomization has previously implicated GLP1R signaling in heart failure 48 , and a randomized controlled trial of the dual GIP/GLP-1 receptor agonist tirzepatide has demonstrated the potential of this class of medications as a therapy for select patients with heart failure 49 .”
Reddy, Y. N. V., Frantz, R. P., Hemnes, A. R., Hassoun, P. M., Horn, E. M., Leopold, J. A., Rischard, F. P., Rosenzweig, E. B., Hill, N. S., ERZURUM, S. C., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.530 · Cited by 45
Self-citationMadsbad, S., & Holst, J. J. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2472408 · Cited by 43
“In the SUMMIT-HFpEF trial, 731 patients with heart failure and an ejection fraction of at least 50% and a BMI >30 kg/m 2 were randomized to tirzepatide up to 15 mg or placebo (Table 3) [89].”
Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity
Lin, H.-T., Tsai, Y.-F., Liao, P.-L., & Wei, J. C.-C. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.21016 · Cited by 43
O'Keefe, J. H., Franco, W. G., & O'Keefe, E. L. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.12.010 · Cited by 42
Westermeier, F., & Fisman, E. Z. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02608-9 · Cited by 45
“As the first trial focus specifically on patients with HFpEF and obesity, the SUMMIT trial provides critical insights that may shape future guidelines for the management of this patient population [30, 31].”
Davies, M. J., Lim, S. K., Slater, T., Goldney, J., Philis‐Tsimikas, A., Franco, D. R., Lamptey, R., Yates, T. E., Tankova, T. I., & Lingvay, I. (2026) · Nature Reviews Disease Primers · doi:10.1038/s41572-026-00687-w · Cited by 63
Galli, M., Abbate, A., Bonaca, M. P., Crea, F., Forte, M., Frati, G., Gaudino, M. F. L., Gibson, C. M., Gorog, D. A., Mehran, R., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01249-z · Cited by 52
Pathak, R. K., Elliott, A. D., Lau, D. H., Middeldorp, M. E., Linz, D., Fitzgerald, J. L., Gupta, A. K., Ariyaratnam, J., Malik, V., Noubiap, J. J., et al. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.4007 · Cited by 43
Pharmacotherapy for metabolic dysfunction-associated steatohepatitis: heart–liver co-management
Zhou, X., Lazarus, J. V., Krittanawong, C., Targher, G., Byrne, C. D., Younossi, Z. M., Tacke, F., Chen, Q., Mantzoros, C. S., Tilg, H., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00323-1 · Cited by 50
New drugs for the treatment of obesity: do we need approaches to preserve muscle mass?
Ryan, D. H. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09967-4 · Cited by 34
“In addition to glycemic and weight loss efficacy, for patients with obesity with or without diabetes, benefits are seen in heart failure with preserved ejection fraction (HFpEF) with semaglutide [8–10] and tirzepatide [11].”
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2025) · Peptides · doi:10.1016/j.peptides.2025.171380 · Cited by 41
“In obese patients with preserved ejection fraction heart failure and without diabetes tirzepatide (up to 15 mg QW for 52 weeks) reduced CV death or worsening heart failure by 38 % [43].”
Packer, M., Zile, M. R., Kramer, C. M., DiMaria, J. M., Baum, S. J., Litwin, S. E., Murakami, M., Zhou, C., Ou, Y., Koeneman, L., et al. (2025) · JACC · doi:10.1016/j.jacc.2025.06.058 · Cited by 34
Self-citationExercise Training in Heart Failure: Clinical Benefits and Mechanisms
Mounsey, L. A., Guo, M., Lau, E. S., & Ho, J. E. (2025) · Circulation Research · doi:10.1161/circresaha.124.325533 · Cited by 43
HFpEF and MASLD: converging mechanisms and clinical implications
Capone, F., Häseli, S. P., Liu, L., Strocchi, S., Langenberg, C., Lusis, A. J., Pietzner, M., Muoio, D. M., Rider, O. J., Raman, B., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01257-z · Cited by 37
“…tirzepatide led to greater weight loss than semaglutide 366,384 , improved exercise capacity and quality of life in patients with HFpEF compared with placebo 385 , and lowered the risk of a composite of death from cardiovascular causes or worsening HF in patients with HFpEF and obesity 386 .”
Hankosky, E. R., Chinthammit, C., Meeks, A., Huang, A., Ward, J. M., Mojdami, D., & Hunter, T. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16290 · Cited by 39
Lin, Y., Liao, K., Yu, T., Wu, J., & Lai, C. (2025) · Nature Communications · doi:10.1038/s41467-025-59616-2 · Cited by 42
Cardiovascular, Kidney, Liver, and Metabolic Interactions in Heart Failure: Breaking Down Silos
Lee, C. J. M., Kosyakovsky, L. B., Khan, M. S., Wu, F., Chen, G., Hill, J. A., Ho, J. E., Foo, R., & Zannad, F. M. (2025) · Circulation Research · doi:10.1161/circresaha.125.325602 · Cited by 39
The real‐life experiences of people living with overweight and obesity: A psychosocial perspective
Flint, S. W., Vázquez‐Velázquez, V., Brocq, S. L., & Brown, A. C. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16255 · Cited by 35
Liu, Z., Yu, S., Jin, X., Sheng, L., Rouzi, M. R. Y., Gao, J., Lü, J., & Lei, T. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s559919 · Cited by 35
Coppi, F., Pagnoni, G., Grossule, F., Nassar, A., Maini, A., Masaracchia, G., Sbarra, F., Battigaglia, E., Maggio, E., Aschieri, D., et al. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12060213 · Cited by 40
“Tirzepatide is the first drug shown to improve cardiovascular outcomes in patients with heart failure and an ejection fraction of no less than 50% [86].”
Ostrominski, J. W., Lassen, M. C. H., Butt, J. H., Claggett, B. L., Anand, I. S., Desai, A. S., Jhund, P. S., Lam, C. S. P., Pfeffer, M. A., Pitt, B., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.012 · Cited by 34
Self-citationWhat Is Cardiometabolic HFpEF and How Can We Study it Preclinically?
Daou, D., Tong, D., Schiattarella, G. G., Gillette, T. G., & Hill, J. A. (2025) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.04.009 · Cited by 37
Tuccinardi, D., Masi, D., Watanabe, M., Zanghi Buffi, V., De Domenico, F., Berti, S., Cipriani, V., Manco, M., Manfrini, S., & Pagotto, U. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02700-7 · Cited by 29
“In patients with HFpEF and obesity, both semaglutide and tirzepatide improve NYHA class, physical function, and quality of life independent of glycemic control, suggesting a glucose and weight-indepen-dent mechanism linked to anti-inflammatory and hemody - namic effects [ 5, 11].”
InfluentialSarcopenic obesity and weight loss-induced muscle mass loss
Caturano, A., Amaro, A., Berra, C., & Conte, C. (2025) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000001131 · Cited by 73
“Both drugs [49,50].”
Central Adiposity or Hypertension
Packer, M., Butler, J., Lam, C. S. P., Zannad, F. M., Vaduganathan, M., & Borlaug, B. A. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.036 · Cited by 32
Self-citationSingh, V., Sun, J. M., Cheng, S. C., Kwan, A. C., & Velazquez, A. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03352-y · Cited by 37
“Both semaglutide and tirzepatide appear to have benefits in composite cardiovascular outcomes within patients with obesity and HFpEF, although the mechanisms are currently unclear [144, 146, 153].”
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100181 · Cited by 28
Packer, M., Lam, C. S. P., Butler, J., Zannad, F. M., Vaduganathan, M., & Borlaug, B. A. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.07.052 · Cited by 32
“159,160 Yet, the magnitude of the improvement is not enhanced in patients who also have diabetes.”
Self-citationOstrominski, J. W., Ortega-Montiel, J., Tesfaye, H., ALIX, C., DiCesare, E., CROMER, S. J., Wexler, D. J., Paik, J. M., & Patorno, E. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-02870 · Cited by 29
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J. P., Butsch, W. S., Christensen, S. M., Gianos, E., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2026.100269 · Cited by 41
Zhang, X., Cao, C., Zheng, F., Liu, C., & Tian, X. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07670-9 · Cited by 27
“…trial, among patients with HFpEF, the dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide agonist, tirzepatide, significantly reduces the combined risk of cardiovascular death or the exacerbation of HF. Specifically, it brings down the hospitalization rate for HF by 38% [68].”
Potential Use of GLP-1 and GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We at?
Janić, M., Škrgat, S., Harlander, M., Lunder, M., Janež, A., Stoian, A. P., El‐Tanani, M., Maggio, V., & Rizzo, M. (2024) · Medicina · doi:10.3390/medicina60122030 · Cited by 33
“However, tirzepatide did not lead to a reduction in cardiovascular deaths alone, in line with the effects observed with semaglutide [82].”
Samson, S. L., Vellanki, P., Blonde, L., Hirsch, I. B., Hoang, T. D., Isaacs, S. D., Izuora, K. E., Wang, C. C. L., Ooi, C. P., Padilla, B. I., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.006 · Cited by 35
Deng, S., Chen, Z., & Shi, Y. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01486-8 · Cited by 30
“Figure created with BioRender.com albiglutide [59–61], dulaglutide [62–64], oral semaglutide [58, 65–67], PEG-loxenatide [68] and tirzepatide [68–73] (Table 1).”
Tailoring Medical Therapy for Heart Failure with Preserved Ejection Fraction
Inciardi, R. M., Riccardi, M., Savarese, G., Metra, M., Vaduganathan, M., & Solomon, S. D. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3558 · Cited by 26
Fernando, K., Connolly, D. L., Darcy, E., Evans, M., Hinchliffe, W., Holmes, P., & Strain, W. D. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01738-3 · Cited by 31
Taylor, E. B., Hall, J. E., & Mouton, A. J. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107761 · Cited by 29
Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era
Pohlman, N., Patel, P. N., Essien, U. R., Tang, J., & Joseph, J. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf295 · Cited by 28
Damman, K., ter Maaten, J. M., Mayne, K. J., Bolignano, D., Brown, E. M., da Costa, B. R., Dagre, A. G., Gansevoort, R. T., Gavina, C., Goette, A., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag098 · Cited by 34
Nissen, S. E., Wolski, K., D’Alessio, D. A., Weerakkody, G. J., Kiljanski, J. I., Wiese, R. J., Pavo, I. J., Cariou, B., & Nicholls, S. J. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2026.0767 · Cited by 25
Self-citationSiddiqui, H. F., Waqas, S. A., Batool, R. M., Salim, H., Minhas, A. M. K., Hasni, S. F., Alsaid, A., Sannino, A., Afzal, A. M., & Khan, M. S. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10523-0 · Cited by 25
“…class, including agents targeting additional receptors like glucose-dependent insulinotropic polypeptide (GIP), significantly reduced the composite of HF hospitalization and cardiovascular death in patients with HF with pre-served ejection fraction (HFpEF), regardless of their T2DM status [3, 4].”
Diabetic cardiomyopathy revisited: The interplay between diabetes and heart failure
Mann, C., Braunwald, E., & Zelniker, T. A. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133554 · Cited by 25
Insights into the Mechanism of Action of Tirzepatide: A Narrative Review
Galindo, R. J., CHENG, A. Y. Y., Longuet, C., Ai, M., Coşkun, T., Malik, R., Peleshok, J. C., Levine, J. A., & Dunn, J. P. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01804-w · Cited by 32
“…City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS) improved significantly among participants in the tirzepa-tide arm compared with those in the placebo arm (between-group difference = 6.9 [95% CI 3.3–10.6]; P < 0.001), indicating self-reported improvement in quality of life [6].”
Influential
Metadata
- Authors
- Packer, M., Zile, M. R., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ge, J., Weerakkody, G. J., Ou, Y., Bunck, M. C., Hurt, K. C., Murakami, M., & Borlaug, B. A.
- Affiliations
- Cleveland Clinic (US)
- From Baylor University Medical Center, Dallas (M.P.); Imperial College, London (M.P.); RHJ Department of Veterans Affairs, Health System and Medical University of South Carolina, Charleston (M.R.Z., S.E.L.); the Cardiovascular Division, Department of Medicine, University of Virginia Health System, Charlottesville (C.M.K.); Flourish Research, Boca Raton, FL (S.J.B.); the Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland (V.M.); the Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China (J.G.); Eli Lilly, Indianapolis (G.J.W., Y.O., M.C.B., K.C.H., M.M.); and the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-01-30
- Volume
- 392
- Issue
- 5
- Pages
- 427-437
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4404437149
- Semantic Scholar
- aeedfcfb5543cef26bd4f4576e1c5a59b4d2424f
- Cited by
- 1,009
- References
- 30
- Citations by year
- 2026: 496 · 2025: 494
- FWCI
- 303.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company (N/A)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- tirzepatide, heart failure with preserved ejection fraction, obesity, GIP/GLP-1 receptor agonist, weight loss, cardiovascular mortality, worsening heart failure, Kansas City Cardiomyopathy Questionnaire, quality of life, body mass index, GLP-1 receptor agonists, GIP receptor agonist, cardiovascular outcomes, weight loss treatment, heart failure with reduced ejection fraction
- MeSH terms
- Tirzepatide, Aged, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Heart Failure, Humans, Male, Middle Aged, Obesity, Quality of Life, Stroke Volume, Weight Loss, Body Mass Index, Treatment Outcome, Glucagon-Like Peptide 1, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.